adnectin 18F-BMS-986192 Head and Neck Cancer for Metastatic Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Yale University PET Center, New Haven, CT
Metastatic Cancers+3 More
adnectin 18F-BMS-986192 Head and Neck Cancer - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using [a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within resected lesions in head and neck cancer and brain metastases.

Eligible Conditions

  • Metastatic Cancers
  • Metastatic Lung Cancer
  • Head Neck Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Metastatic Cancers

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: from with in 2 weeks perioperative up to postoperative

Week 2
Immunohistochemistry vs PET measure of PD-L1 levels in head and neck cancer locoregional neck metastatic lesions and resected normal lymph nodes
Immunohistochemistry vs PET measure of PD-L1 levels in head and neck cancer primary lesion
Immunohistochemistry vs PET measure of PD-L1 levels within resected brain metastasis tumor cells
Immunohistochemistry vs PET measure of infiltrating inflammatory cells in head and neck cancer locoregional neck metastatic lesions and resected normal lymph nodes
Immunohistochemistry vs PET measure of infiltrating inflammatory cells in head and neck cancer primary lesion
Non-invasive quantitative PD-L1 levels will be measured using PET measures (VT) of lesions for the groups of PD-L1 levels (PD-L1 ≥90% vs <1%, PD-L1 ≥50% vs <1%) in head and neck cancer primary lesions

Trial Safety

Safety Progress

1 of 3

Other trials for Metastatic Cancers

Trial Design

2 Treatment Groups

Head and neck cancer
1 of 2
Brain Metastases
1 of 2
Experimental Treatment

24 Total Participants · 2 Treatment Groups

Primary Treatment: adnectin 18F-BMS-986192 Head and Neck Cancer · No Placebo Group · Phase 1

Head and neck cancer
Drug
Experimental Group · 1 Intervention: adnectin 18F-BMS-986192 Head and Neck Cancer · Intervention Types: Drug
Brain Metastases
Drug
Experimental Group · 1 Intervention: adnectin 18F-BMS-986192 Brain Metastases · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from with in 2 weeks perioperative up to postoperative
Closest Location: Yale University PET Center · New Haven, CT
Photo of New Haven 1Photo of New Haven 2Photo of New Haven 3
2016First Recorded Clinical Trial
1 TrialsResearching Metastatic Cancers
2 CompletedClinical Trials

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,653 Previous Clinical Trials
20,829,940 Total Patients Enrolled
1 Trials studying Metastatic Cancers
13 Patients Enrolled for Metastatic Cancers
National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,294,436 Total Patients Enrolled
160 Trials studying Metastatic Cancers
24,997 Patients Enrolled for Metastatic Cancers
Mariam S Aboian, MD PhDPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients with resectable squamous cell carcinoma of the oropharynx (HPV positive and HPV negative).
You are a woman of child-bearing potential and have a negative serum pregnancy test within 7 days prior to treatment.
You are eligible for surgery if you have resectable cancer.
Albumin > 0 g/dl.
You have a tumor size of 1 cm or greater.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.